Long-Term Care

How Long Should You Stay on GLP-1 Medications?

GLP-1 Companion · 8 min read

When a patient starts Ozempic, Wegovy, Mounjaro, or Zepbound, a natural question emerges: how long do I need to take this? The answer has shifted significantly over the past decade as our understanding of obesity as a biological disease — rather than a failure of willpower — has matured. The evidence now points clearly toward long-term, potentially indefinite treatment for most patients.

Obesity Is a Chronic Disease Requiring Chronic Treatment

The foundational principle behind long-term GLP-1 use is that obesity is classified as a chronic, relapsing disease by every major medical organization — including the World Health Organization, the American Medical Association, and the American Society of Metabolic and Bariatric Surgery. Chronic diseases require chronic management. We do not expect hypertension to permanently resolve after taking a blood pressure medication for a year. The same logic applies to obesity.

Obesity is a chronic, relapsing, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences. — Obesity Medicine Association

What Happens When You Stop: The STEP 1 Extension Data

The most compelling argument for long-term GLP-1 use comes from the STEP 1 extension study, published in 2022 in Diabetes, Obesity and Metabolism. In this study, participants who had completed the 68-week STEP 1 trial (achieving an average 17.3% weight loss on semaglutide 2.4mg) were taken off medication and monitored for an additional 52 weeks with lifestyle support only. The results were stark.

• 66% of the weight lost during the trial was regained within one year of stopping semaglutide.
• Cardiometabolic improvements — including blood pressure, lipids, and HbA1c — largely reversed.
• Participants on placebo extension continued to gain weight across the follow-up period.
• By 20 weeks off medication, the divergence between those who stopped and those who continued (in a separate ongoing arm) was already pronounced.

What Major Professional Societies Now Recommend

In response to the accumulating evidence, major medical organizations have updated their guidelines to reflect a long-term treatment paradigm for GLP-1 medications in obesity.

• American Diabetes Association (ADA): Recommends ongoing use of GLP-1 receptor agonists for weight management in appropriate patients, analogous to antihypertensive or statin therapy.
• American Association of Clinical Endocrinology (AACE): Endorses long-term pharmacotherapy as part of comprehensive obesity management; no defined maximum duration.
• Obesity Medicine Association (OMA): Explicitly frames obesity medications as chronic disease therapies, not short-term interventions, and recommends continuation as long as benefit is maintained and side effects are tolerable.
• American Heart Association and American College of Cardiology: Following cardiovascular outcome trial data (SELECT trial for semaglutide), support ongoing use for patients with established cardiovascular disease and obesity.

The Analogy to Other Chronic Disease Medications

The clearest way to understand long-term GLP-1 use is through the lens of other chronic disease medications. We do not question whether a patient needs to stay on their blood pressure medication, their cholesterol-lowering statin, or their thyroid hormone replacement — because we accept that these are ongoing biological needs. The same principle applies to GLP-1 medications for obesity. Stopping the medication without addressing the underlying chronic disease — the dysregulated appetite signaling, the set point biology — leads to predictable disease recurrence.

Is There a Maximum Duration?

No clinical guideline currently establishes a maximum duration for GLP-1 medication use. Long-term safety data from trials extending beyond two years (and real-world data now extending to five or more years) have not revealed new concerning safety signals with continued use. The longest-running outcome trials — including the SUSTAIN-6 and LEADER trials with liraglutide — followed patients for three or more years without identifying new safety concerns associated with extended duration.

The Concept of Maintenance Dosing

An emerging concept in obesity medicine is maintenance dosing — the idea that some patients who achieve their weight goal may be able to taper to a lower dose rather than maintain the maximum therapeutic dose indefinitely. A patient who achieved their goals on semaglutide 2.4mg might maintain successfully on 1mg or 1.7mg, reducing cost and potentially further improving tolerability. This approach is not yet well-studied with large trial data, but providers increasingly explore it in practice. If any dose reduction triggers appetite return or weight regain, returning to the full therapeutic dose is appropriate.

When It May Be Appropriate to Stop

Long-term use is the recommended approach for most patients, but there are circumstances where stopping or pausing GLP-1 medications is appropriate. These include intolerable side effects that do not resolve with dose adjustment, pregnancy (GLP-1 medications are not approved for use in pregnancy), prior to planned surgery (providers typically hold GLP-1 medications before anesthesia due to gastroparesis risk), or when a patient and provider determine the risk-benefit balance has shifted.

• Pregnancy: GLP-1 medications should be discontinued before conception and are contraindicated in pregnancy.
• Planned surgery: Many anesthesiologists require holding GLP-1 medications 1–2 weeks prior to general anesthesia.
• Persistent intolerable side effects: If dose reduction does not resolve severe GI symptoms, stopping may be appropriate.
• Medication interactions: Rarely, new medications create interactions requiring discontinuation.
• Patient preference: Informed patients have the right to make treatment decisions with full knowledge of the likely outcomes.

A Framework for the Long-Term Conversation

The most productive framing for the "how long" question is not "when can I stop?" but rather "what am I treating, and does that condition resolve?" For most patients with obesity, the condition does not resolve — it is managed. That management may look different over time: different doses, potentially different medications as new options emerge, periods of closer monitoring, or eventual maintenance dosing. But the weight-regain data makes clear that the majority of patients who stop GLP-1 medications entirely will regain most of their lost weight within one to two years, along with the metabolic improvements that weight loss conferred. For most patients, long-term treatment is not just an option — it is the evidence-based choice.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.